Novartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
(WorldNews Switzerland)

CHMP opinion based on pivotalPhase III trial thatshowedKisqali plus letrozole reduced risk of disease progression or death by 44% over letrozole alone among postmenopausal women with HR+/HER2- advanced breast cancer[1] After nearly one year of additional follow-up, Kisqali plus letrozole demonstrated median progression-free survival (PFS) of 25.3 months compared to 16.0 months for letrozole alone[2] Worldwide, an estimated 250,000 women will be diagnosed with advanced breast cancer each year[3] The digital press release with multimedia content can be accessed here: Basel, June 23, 2017- Novartis today announced the Committee for Medicinal Products for Human Use (CHMP) of the European...